Literature DB >> 19593085

Nonmyeloablative and reduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation: a clinical review.

Seth M Pollack1, Thomas P O'Connor, Jana Hashash, Imad A Tabbara.   

Abstract

Allogeneic hematopoietic stem cell transplantation provides many patients, with hematological and malignant diseases, hope of remission and in some cases cure. Because the toxicities of this approach are severe, its use has been limited to younger healthier patients. Nonmyeloablative and reduced intensity conditioning regimens depend more on donor cellular immune effects and less on the cytotoxic effects of the conditioning regimen to eradicate the underlying disease. This approach is based on the induction of host tolerance to donor cells followed by the administration of scheduled donor T-lymphocytes infusions. Accumulated clinical data have been encouraging, and prospective studies are underway to compare this approach to conventional myeloablative allogeneic stem cell transplantation with regard to outcome, durability of responses, effects on the immune system, and the consequences of late complications such as chronic graft-versus-host disease.

Entities:  

Mesh:

Year:  2009        PMID: 19593085     DOI: 10.1097/COC.0b013e31817f9de1

Source DB:  PubMed          Journal:  Am J Clin Oncol        ISSN: 0277-3732            Impact factor:   2.339


  7 in total

Review 1.  Indications and outcomes of reduced-toxicity hematopoietic stem cell transplantation in adult patients with hematological malignancies.

Authors:  S Fadilah Abdul Wahid
Journal:  Int J Hematol       Date:  2013-04-13       Impact factor: 2.490

2.  Effects of sublethal irradiation on patterns of engraftment after murine bone marrow transplantation.

Authors:  Jacob Andrade; Shundi Ge; Goar Symbatyan; Michael S Rosol; Arthur J Olch; Gay M Crooks
Journal:  Biol Blood Marrow Transplant       Date:  2010-12-19       Impact factor: 5.742

3.  Ocular complications in children after hematopoietic stem cell transplantation without total body irradiation.

Authors:  Michael Kinori; Bella Bielorai; Daniel Souroujon; Dafna Hutt; Iris Ben-Bassat Mizrachi; Ruth Huna-Baron
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2015-02-24       Impact factor: 3.117

Review 4.  Promising role of reduced-toxicity hematopoietic stem cell transplantation (PART-I).

Authors:  S Abdul Wahid Fadilah; Md Pazil Aqilah
Journal:  Stem Cell Rev Rep       Date:  2012-12       Impact factor: 5.739

5.  Perivascular, but not parenchymal, cerebral engraftment of donor cells after non-myeloablative bone marrow transplantation.

Authors:  Yue Yang; Nikolas L Jorstad; Christine Shiao; Makenzie K Cherne; Shawn B Khademi; Kathleen S Montine; Thomas J Montine; C Dirk Keene
Journal:  Exp Mol Pathol       Date:  2013-04-06       Impact factor: 3.362

Review 6.  Adoptive T-cell therapy for Leukemia.

Authors:  Haven R Garber; Asma Mirza; Elizabeth A Mittendorf; Gheath Alatrash
Journal:  Mol Cell Ther       Date:  2014-08-12

7.  Dissecting the mechanisms involved in anti-human T-lymphocyte immunoglobulin (ATG)-induced tolerance in the setting of allogeneic stem cell transplantation - potential implications for graft versus host disease.

Authors:  Katia Beider; David Naor; Valeria Voevoda; Olga Ostrovsky; Hanna Bitner; Evgenia Rosenberg; Nira Varda-Bloom; Victoria Marcu-Malina; Jonathan Canaani; Ivetta Danilesko; Avichai Shimoni; Arnon Nagler
Journal:  Oncotarget       Date:  2017-10-11
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.